Endometrial Cancer Clinical Trials in Linköping
2 recruitingLinköping, Sweden
Showing 1–2 of 2 trials
Recruiting
Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca600 enrolled249 locationsNCT06989112
Recruiting
Phase 2Phase 3
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Kartos Therapeutics, Inc.268 enrolled83 locationsNCT05797831